Protea Biosciences Group, Inc. 4
4 · Protea Biosciences Group, Inc. · Filed Jan 8, 2016
Insider Transaction Report
Form 4
SEGAL SCOTT
Director
Transactions
- Other
Common Stock
2015-03-31+418,552→ 2,375,713 total - Other
Common Stock
2015-03-31+10,464→ 2,386,177 total - Award
Common Stock
2015-12-18+80,000→ 2,466,177 total - Award
Director Stock Option (right to buy)
2015-12-18+66,667→ 66,667 totalExercise: $0.25From: 2016-12-01Exp: 2025-12-01→ Common Stock (66,667 underlying)
Footnotes (3)
- [F1]The Reporting Person held 52,319 shares of the Issuer's Series A Convertible Stock (the "Preferred Shares") with a stated value equal to $2.00 per share (the "Stated Value"). On March 31, 2015, the Preferred Shares automatically converted into shares of the Issuer's common stock (the "Common Stock") determined by dividing the Stated Value by $0.25 per share, resulting in the issuance of 418,552 shares of Common Stock to the Reporting Person.
- [F2]The Preferred Shares were entitled to receive dividends payable in Common Stock at the rate of 6.0% per annum, which were paid on March 31, 2015.
- [F3]The option vests 100% on December 1, 2016.